DNA polymerase IIIC inhibitor - Acurx Pharmaceuticals
Latest Information Update: 02 Jan 2026
At a glance
- Originator Acurx Pharmaceuticals
- Class Anti-infectives
- Mechanism of Action DNA polymerase III inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Skin and soft tissue infections; Ventilator associated pneumonia